Is FDA Trial Design Scrutiny Increasing or Just Less Predictable?
In this video interview, Meri Beckwith, Co-CEO of Lindus Health, discusses whether recent trial design rejections signal a broader shift in FDA expectations or simply reflect changes in individual reviewers, emphasizing that current unpredictability may be more situational than systemic.
In a recent video interview with Applied Clinical Trials, Meri Beckwith, Co-CEO, Lindus Health, discussed the evolving perception of breakthrough designation amid the FDA’s recent
ACT: Do you think the growing scrutiny around trial design is a sign of regulatory unpredictability, or are we seeing more transparent expectations from the FDA that just haven’t been operationalized effectively yet?
Beckwith: I’m not sureI'd quite say that there is more scrutiny, or there's a pattern of more scrutiny, on trial design. I do think in this case, it just seems to be kind of like a personally driven issue with a few kind of personalities inside the FDA. Having said that though, maybe over the next year or two, there's a pretty consistent pattern of the FDA rejecting more studies that aren't controlled or insisting on more robust results, more carefully scrutinizing sample sizes, those kinds of things, remains to be seen. My view is that these decisions, it's just kind of unpredictability, the result of one set of reviewers, maybe transitioning off or out of the FDA, and then a different set of reviewers with a different perspective coming in. That does make me hopeful that this will be an isolated case of just regulatory unpredictability rather than a sort of raising of the bar, but it remains to be seen.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Modernizing Clinical Trials: A Site-Centered Roadmap for the Future
September 24th 2025
- Using Model-Informed Drug Development to Support OS Endpoints
September 24th 2025
- Areas of Opportunity for AI in Clinical Research
September 23rd 2025
- How FDA’s Focus on Overall Survival Redefines Trial Success
September 23rd 2025